Candesartan in migraine prevention: results from a retrospective real-world study

Roberta Messina; Carlo Piero Lastarria Perez; Massimo Filippi; Peter J. Goadsby

doi:10.1007/s00415-020-09989-9

Article2025

A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II)

Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Alberto Doretti, Florindo d’Onofrio, Paola Scatena, Steno Rinalduzzi, Luisa Vinciguerra, Mattia Sansone, Rosario Vecchio, Valeria Drago, Giovanna Viticchi, Marco Bartolini, Angelo Ranieri, M. Poggio, Francesco Baldisseri, Davide Mascarella, Fabio Brusaferri, Luigi Caputi, Stefano Messina, Massimo Autunno, Alessandro Valenza, Bianca Orlando, Marisa Distefano, L. Borrello, Francesca Pistoia, Cecilia Camarda, Gennaro Saporito, Giacomo Querzola, Paola Torelli, Antonio Salerno, Francesca Gragnani, Barbara Petolicchio, Antonio Carnevale, Roberta Messina, Massimo Filippi, Sofia Tavani, Giulia Fiorentini, Stefano Bonassi, Sabina Cevoli, Alice Mannocci

Article2021

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study

Luisa Fofi, Gabriella Egeo, Cinzia Aurilia, Carmelina Maria Costa, Claudia Altamura, Fabrizio Vernieri, Maria Albanese, Florindo d’Onofrio, Laura Di Clemente, Maurizio Zucco, Paola Di Fiore, Fabio Frediani, Roberta Messina, Bruno Colombo, Massimo Filippi, Francesco Bono, Lucia Manzo, Antonio Carnevale, Piero Barbanti, Stefania Proietti, Stefano Bonassi

Article2021

Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

Piero Barbanti, Cinzia Aurilia, Sabina Cevoli, Gabriella Egeo, Luisa Fofi, Roberta Messina, Antonio Salerno, Paola Torelli, Maria Albanese, Antonio Carnevale, Francesco Bono, Domenico D’Amico, Massimo Filippi, Claudia Altamura, Fabrizio Vernieri

Preprint2023

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results from the Real-World, Retrospective EMN23 Study

Arnaud Jaccard, Frank Bridoux, Wilfried Roeloffzen, Monique C. Minnema, Rui Bergantim, Roman Hájek, Cristina João, M. Teresa Cibeira, Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, Paolo Milani, Meletios A Dimopoulos, Sriram Ravichandran, Ute Hegenbart, Hermine Agis, Blanca Gros, A Asra, Valeria Magarotto, Giorgos Cheliotis, Giorgos Psarros, Pieter Sonneveld,

Article2024

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study